Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
$198.85
+1.8%
$200.27
$144.54
$210.24
$23.42B0.98388,730 shs437,685 shs
Humana Inc. stock logo
HUM
Humana
$320.54
-0.1%
$324.12
$298.61
$541.21
$38.63B0.491.61 million shs1.80 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$149.27
-0.4%
$154.19
$143.13
$175.97
$359.24B0.558.67 million shs6.53 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
-0.05%+2.42%+0.13%-1.43%+28.22%
Humana Inc. stock logo
HUM
Humana
-0.02%+4.79%+3.39%-15.40%-39.50%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.00%+2.14%-2.11%-4.69%-8.35%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
4.295 of 5 stars
1.23.04.23.23.82.51.9
Humana Inc. stock logo
HUM
Humana
4.9967 of 5 stars
4.23.03.33.91.83.33.1
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9008 of 5 stars
3.23.04.23.93.02.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
2.43
Hold$206.673.93% Upside
Humana Inc. stock logo
HUM
Humana
2.47
Hold$424.5032.43% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8617.81% Upside

Current Analyst Ratings

Latest BR, HUM, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Humana Inc. stock logo
HUM
Humana
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$415.00 ➝ $353.00
4/25/2024
Humana Inc. stock logo
HUM
Humana
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$391.00 ➝ $360.00
4/25/2024
Humana Inc. stock logo
HUM
Humana
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$334.00 ➝ $326.00
4/25/2024
Humana Inc. stock logo
HUM
Humana
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$415.00 ➝ $370.00
4/22/2024
Humana Inc. stock logo
HUM
Humana
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$411.00 ➝ $381.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/10/2024
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$185.00
(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
$6.06B3.86$10.67 per share18.63$18.99 per share10.47
Humana Inc. stock logo
HUM
Humana
$106.37B0.36$34.28 per share9.35$134.32 per share2.39
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.22$13.67 per share10.92$29.09 per share5.13

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
$630.60M$5.7434.6423.67N/A10.82%41.12%10.58%5/8/2024 (Confirmed)
Humana Inc. stock logo
HUM
Humana
$2.49B$16.0619.9615.371.861.82%17.76%5.63%8/7/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.3113.662.4645.26%36.70%15.07%7/18/2024 (Estimated)

Latest BR, HUM, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
$2.23N/A-$2.23N/AN/AN/A  
4/24/2024Q1 24
Humana Inc. stock logo
HUM
Humana
$6.12$7.23+$1.11$8.35$28.52 billion$29.61 billion      
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
$3.201.61%+11.00%55.75%17 Years
Humana Inc. stock logo
HUM
Humana
$3.541.10%+12.29%22.04%7 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.19%+5.70%29.68%63 Years

Latest BR, HUM, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/18/2024
Humana Inc. stock logo
HUM
Humana
quarterly$0.88501.09%6/28/20246/28/20247/26/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/15/2024
Humana Inc. stock logo
HUM
Humana
quarterly$0.88500.97%3/27/20243/29/20244/26/2024
2/16/2024
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
quarterly$0.801.6%3/14/20243/15/20244/5/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
1.77
1.40
1.40
Humana Inc. stock logo
HUM
Humana
0.77
1.67
1.67
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.36
1.17
0.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
90.03%
Humana Inc. stock logo
HUM
Humana
92.38%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%

Insider Ownership

CompanyInsider Ownership
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
1.60%
Humana Inc. stock logo
HUM
Humana
0.32%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
14,700117.77 million115.89 millionOptionable
Humana Inc. stock logo
HUM
Humana
67,600120.50 million120.12 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.40 billionOptionable

BR, HUM, and JNJ Headlines

SourceHeadline
Johnson & Johnson’s Strategic Settlement Plan Bolsters Buy RatingJohnson & Johnson’s Strategic Settlement Plan Bolsters Buy Rating
markets.businessinsider.com - May 5 at 5:47 PM
Compass Capital Management Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)Compass Capital Management Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)
marketbeat.com - May 5 at 6:47 AM
Johnson & Johnson (NYSE:JNJ) Trading Down 1%Johnson & Johnson (NYSE:JNJ) Trading Down 1%
americanbankingnews.com - May 5 at 4:38 AM
Johnson & Johnson (NYSE:JNJ) Shares Sold by Fifth Third BancorpJohnson & Johnson (NYSE:JNJ) Shares Sold by Fifth Third Bancorp
marketbeat.com - May 4 at 10:43 PM
Shareholders in Johnson & Johnson (NYSE:JNJ) are in the red if they invested three years agoShareholders in Johnson & Johnson (NYSE:JNJ) are in the red if they invested three years ago
finance.yahoo.com - May 3 at 10:10 PM
Johnson & Johnson (NYSE:JNJ)  Shares Down 1% Johnson & Johnson (NYSE:JNJ) Shares Down 1%
marketbeat.com - May 3 at 9:54 PM
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should KnowJohnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
zacks.com - May 3 at 10:01 AM
3 Dividend Growth Stocks that Just Raised Their Payouts3 Dividend Growth Stocks that Just Raised Their Payouts
fool.com - May 3 at 8:30 AM
Retirement Systems of Alabama Trims Holdings in Johnson & Johnson (NYSE:JNJ)Retirement Systems of Alabama Trims Holdings in Johnson & Johnson (NYSE:JNJ)
marketbeat.com - May 3 at 5:51 AM
Johnson & Johnson Proposes $6.5 Billion in New Talc Settlement OfferJohnson & Johnson Proposes $6.5 Billion in New Talc Settlement Offer
nytimes.com - May 3 at 3:18 AM
Johnson & Johnson offers $6.5 billion settlement in baby powder cancer lawsuitsJohnson & Johnson offers $6.5 billion settlement in baby powder cancer lawsuits
yahoo.com - May 2 at 10:18 PM
Johnson & Johnson (NYSE:JNJ) Shares Sold by Hunter Perkins Capital Management LLCJohnson & Johnson (NYSE:JNJ) Shares Sold by Hunter Perkins Capital Management LLC
marketbeat.com - May 2 at 9:21 PM
Johnson & Johnson (NYSE:JNJ) Trading Down 0.6%Johnson & Johnson (NYSE:JNJ) Trading Down 0.6%
marketbeat.com - May 2 at 2:47 PM
Hold Rating on Johnson & Johnson Amid Ongoing Talc Litigation Uncertainties and Settlement EffortsHold Rating on Johnson & Johnson Amid Ongoing Talc Litigation Uncertainties and Settlement Efforts
markets.businessinsider.com - May 2 at 12:12 PM
Johnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and OutlookJohnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and Outlook
markets.businessinsider.com - May 2 at 12:12 PM
Janssen-Cilag seeks expanded EMA approval for TREMFYAJanssen-Cilag seeks expanded EMA approval for TREMFYA
pharmaceutical-technology.com - May 2 at 12:12 PM
Mastering Stocks in the Dow: Insights into the DJIA (JNJ)Mastering Stocks in the Dow: Insights into the DJIA (JNJ)
marketbeat.com - May 2 at 11:32 AM
Decoding Johnson & Johnson (JNJ): A Strategic SWOT InsightDecoding Johnson & Johnson (JNJ): A Strategic SWOT Insight
finance.yahoo.com - May 2 at 7:10 AM
The top pharmaceutical companies by R&D expenditureThe top pharmaceutical companies by R&D expenditure
pharmaceutical-technology.com - May 2 at 7:10 AM
Raymond James Financial Services Advisors Inc. Acquires 88,849 Shares of Johnson & Johnson (NYSE:JNJ)Raymond James Financial Services Advisors Inc. Acquires 88,849 Shares of Johnson & Johnson (NYSE:JNJ)
marketbeat.com - May 1 at 11:06 PM
Johnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuitsJohnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuits
finance.yahoo.com - May 1 at 6:01 PM
US STOCKS-S&P 500, Nasdaq end lower after Fed rate decision, Powell press conferenceUS STOCKS-S&P 500, Nasdaq end lower after Fed rate decision, Powell press conference
finance.yahoo.com - May 1 at 6:01 PM
Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices PlungeStock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge
investorplace.com - May 1 at 3:57 PM
Johnson & Johnson (NYSE:JNJ) Shares Up 4.4%Johnson & Johnson (NYSE:JNJ) Shares Up 4.4%
marketbeat.com - May 1 at 1:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Broadridge Financial Solutions logo

Broadridge Financial Solutions

NYSE:BR
Broadridge Financial Solutions, Inc. provides investor communications and technology-driven solutions for the financial services industry. The company's Investor Communication Solutions segment processes and distributes proxy materials to investors in equity securities and mutual funds, as well as facilitates related vote processing services; and distributes regulatory reports, class action, and corporate action/reorganization event information, as well as tax reporting solutions. It also offers ProxyEdge, an electronic proxy delivery and voting solution; data-driven solutions and an end-to-end platform for content management, composition, and omni-channel distribution of regulatory, marketing, and transactional information, as well as mutual fund trade processing services; solutions for public corporations and mutual funds; data and analytics solutions; SEC filing and capital markets transaction services; registrar, stock transfer, and record-keeping services; and omni-channel customer communications solutions, as well as operates Broadridge Communications Cloud platform that creates, delivers, and manages communications and customer engagement activities. Its Global Technology and Operations segment provides solutions that automate the front-to-back transaction lifecycle of equity, mutual fund, fixed income, foreign exchange and exchange-traded derivatives, order capture and execution, trade confirmation, margin, cash management, clearing and settlement, reference data management, reconciliations, securities financing and collateral management, asset servicing, compliance and regulatory reporting, portfolio accounting, and custody-related services. This segment also offers business process outsourcing services; technology solutions, such portfolio management, compliance, fee billing, and operational support solutions; and capital market and wealth and investment management solutions. The company was founded in 1962 and is headquartered in Lake Success, New York.
Humana logo

Humana

NYSE:HUM
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.